Online Database of Chemicals from Around the World

Milk Thistle Extract
[CAS 84604-20-6]

List of Suppliers
Simagchem Corporation China
www.simagchem.com
+86 13806087780
+86 (592) 268-0237
sale@simagchem.com
Chemical manufacturer since 2002
chemBlink Standard supplier since 2008
Alfa Chemistry USA
www.alfa-chemistry.com
+1 (516) 734-6573
+1 (516) 927-0118
support@alfa-chemistry.com
Chemical manufacturer since 2005
chemBlink Standard supplier since 2012
Ningbo Gianon Biotech Co., Ltd. China
www.gianon.com
+86 (574) 8681-8337
+86 (574) 8681-8226
chenlidan1@126.com
QQ Chat
Chemical manufacturer since 2010
chemBlink Standard supplier since 2014
Forward Farma Inc USA
www.forwardfarma.com
+1 (909) 963-1481
xiaye@forwardfarma.com
Chemical distributor since 2012
chemBlink Standard supplier since 2017
Chemsun Coporation Co., Ltd. China
www.aozhuo.com
+86 15615165502
nancy@chemsunco.com
Chemical manufacturer since 2016
chemBlink Standard supplier since 2023
Nutrition BioTech USA Inc. USA
www.naturalbestbio.com
+1 (909) 745-1357
sales@naturalbestbio.com
Chemical manufacturer since 2024
chemBlink Standard supplier since 2026

Identification
ClassificationBiochemical >> Plant extracts
NameMilk Thistle Extract
Synonyms3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
Molecular StructureMilk Thistle Extract molecular structure (CAS 84604-20-6)
Molecular FormulaC25H22O10
Molecular Weight482.44
CAS Registry Number84604-20-6
EC Number283-298-7
SMILESCOC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
Properties
Density1.144 g/mL (Expl.)
Melting point167 °C (Expl.)
Safety Data
Hazard Symbolssymbol   GHS08 Warning  Details
Risk StatementsH361-H373  Details
Safety StatementsP203-P260-P280-P318-P319-P405-P501  Details
Hazard Classification
up    Details
HazardClassCategory CodeHazard Statement
Skin sensitizationSkin Sens.1H317
Flammable liquidsFlam. Liq.3H226
Chronic hazardous to the aquatic environmentAquatic Chronic3H412
Flammable liquidsFlam. Liq.2H225
Eye irritationEye Irrit.2H319
Specific target organ toxicity - single exposureSTOT SE3H335
Skin irritationSkin Irrit.2H315
SDSAvailable
up chemBlink Chemical Story
A botanical extract can have a registry number without having one molecular structure. Milk thistle extract, obtained from Silybum marianum, is a case in point. Its signature fraction is silymarin, a mixture rather than the name of a single pure substance. The fraction contains several related flavonolignans. Even the better-known term silibinin, or silybin, ordinarily refers to two closely related forms, silybin A and silybin B. This nested vocabulary explains why a label reporting the amount of extract cannot be read as a measurement of a particular flavonolignan.

Chemically, the flavonolignans bring together elements of flavonoid and lignan chemistry. Related components can differ in how fragments are connected or in their three-dimensional arrangements. Compounds with the same formula can therefore behave differently in a chromatographic separation. Analytical laboratories can use a pattern of peaks to characterize an extract and compare lots. To interpret such a fingerprint, it matters which peaks were identified, which were quantified, and whether a reported percentage refers to one component or to a group.

The plant was historically used for liver complaints. Modern investigations have turned this broad tradition into specific testable questions. The US National Toxicology Program characterized a milk thistle extract used in its animal feeding studies. The value of that characterization is not that the results automatically apply to any product with the same common name. It is that the composition and conditions of the experiment become easier to trace. An extract prepared from a different starting material or by a different process need not match the one used in the report.

A randomized trial published in 2012 illustrates a second kind of specificity. Fried and colleagues studied oral silymarin in people with chronic hepatitis C who had previously received interferon-based therapy without success. The trial did not find a significant advantage over placebo on its prespecified serum alanine aminotransferase outcome. That result concerns the preparation, population and endpoint studied. It neither establishes a benefit for other conditions nor rules out every biological effect of all components. The US National Center for Complementary and Integrative Health similarly concludes that the clinical evidence does not permit firm conclusions about effects on health conditions.

There is also a distinction between chemical quality and clinical benefit. A batch with a reproducible profile allows investigators to ask whether repeated experiments are testing similar material. The profile does not itself answer whether a patient benefits. Conversely, if a trial has a clinically relevant outcome, inadequate information about the extract can make it difficult to connect that result to another preparation. The two kinds of evidence support one another without being interchangeable. This is one reason reports that name the extract, describe its components and state the endpoint are more useful than a broad claim about the plant alone. They give future investigators enough information to judge what a replication would actually require.

The endpoint in the hepatitis C study also illustrates how a routine measurement fits into an experiment. Alanine aminotransferase is an enzyme measured in blood that can serve as a marker of liver injury. An enzyme reading is neither a count of virus particles nor a direct measurement of every way a patient might feel or function. The study defined in advance what change would qualify on the primary outcome. A precise account of a negative trial therefore keeps both the measured quantity and the threshold in view, rather than reducing the result to a verdict on the plant.

For researchers, the complexity is a reason to be more precise, not to set the extract aside. Biological observations can be linked to a characterized batch or to one isolated component. For readers, distinguishing the plant, its extract, the silymarin fraction and a single constituent is the first step in deciding whether two reports are actually talking about the same material.

References:
1. US National Toxicology Program. Milk thistle extract, Technical Report 565. https://ntp.niehs.nih.gov/sites/default/files/ntp/htdocs/lt_rpts/tr565.pdf
2. Fried MW et al. Effect of silymarin on liver disease in chronic hepatitis C: randomized controlled trial. JAMA. 2012;308:274–282. https://pubmed.ncbi.nlm.nih.gov/22797645/
3. NCCIH. Milk thistle: usefulness and safety. https://www.nccih.nih.gov/health/milk-thistle

Market Analysis Reports
Related Products
Milbex  Mildiomycin  Mildronate  Mildronate dihy...  Milenperone  Miliacin  Milipertine  Militarine  Milk  Milk lactone  Millettone  Millewanin G  Millewanin H  Milliamine  Milliamine H  Milliamine I  Millisorin B  Milnacipran  (+)-(1S,2R)-MIL...  Milnacipran Car...